Huntington's Disease | Epidemiology | Mature Markets Data

Publish date: July 2018

Login to access report

DRG Epidemiology’s coverage of Huntington’s Disease comprises epidemiological estimates of key patient populations in seven major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of the disease for each country, as well as annualized case counts projected to the national population.

In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities at specific lines of therapy in the major mature pharmaceutical markets.

DRG Epidemiology’s Huntington’s Disease forecast will answer the following questions:

  • Of all people diagnosed with Huntington’s Disease, how many in each of the major mature pharmaceutical markets under study are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of Huntington’s Disease over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following  Huntington’s Disease subpopulations:

  • Diagnosed Prevalence of Huntington’s Disease.
  • Diagnosed Incident Cases of Huntington’s Disease.
  • Diagnosed Prevalent Cases of Huntington’s Disease by Treatment Status.

Note: Coverage may vary by country.

Table of contents

  • Mature Markets Data
    • Introduction
      • Key Findings
        • Relative Sizes of the Contributing Factors to the Trend in Prevalent Cases of Huntington's disease over the Next 20 Years
    • Methods
      • Diagnosed Prevalent Cases
      • Drug-Treated Diagnosed Prevalent Cases
      • Diagnosed Incident cases
    • Epidemiology Data
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Johnson Olabisi, MBBS, MSc; Nishant Kumar, MPH

Johnson joined Decision Resources Group (DRG) in 2015 and with the Epidemiology team develops epidemiological populations forecasts for different infectious and non-communicable diseases with his particular interests in the oncology space. Prior to joining DRG, he trained as a community physician where he was involved in primary (patient) care, primary health care and various community research & activities. He has also supervised and coordinated various governmental and non-governmental public health projects. Johnson holds a Masters of Science in Public Health (Health Economics) degree from the London School of Hygiene and Tropical Medicine with a Masters in Epidemiology and Medical Statistics & a Medical degree from the University of Ibadan, Nigeria.  

Nishant is a senior epidemiologist and head of oncology within the epidemiology team at Decision Resources Group. He also covers some CNS diseases, including Alzheimer’s disease and dementia. His key interests are developing interactive patient flows, and modelling disease progression to forecast commercially relevant drug-treatable incident and prevalent populations. Nishant also spends a lot of time collaborating with clients to help answer more specific questions through custom work and consulting projects. His qualifications include an MSc in Public Health with specialization in epidemiology and statistics from King’s College London, and a BSc in Medical Studies from the University of Birmingham.